Skip to main content

This website is no longer being updated. Visit Dartmouth Now for all news published after June 7, 2010.


Dartmouth News
>  News Releases >   2003 >   April

Dartmouth patents, 1999 to present

Posted 04/07/03

Below is a list of 28 patents issued to Dartmouth researchers in the United States between 1999 and the present. Half of them are licensed, meaning a private company has purchased the rights to manufacture and sell an invention on the market. Aside from the U.S. patents listed below, 62 patents were issued to the Trustees of Dartmouth College in foreign countries during the same time period, most of which were licensed. This information is provided by the Technology Transfer Office, which is responsible for shepherding Dartmouth inventions through the process of patenting and licensing.

Inventor: Hillary D. White

Patent Title: Use of Androgen Therapy in Fibromyalgia and Chronic Fatigue Syndrome
Abstract: A method of using androgen therapy to alleviate symptoms associated with chronic fatigue syndrome and fibromyalgia syndrome is provided.
Patent Number: 5,935,949
Filed: 03-10-1999
Issued: 08-10-1999
Licensed to: Bentley Pharmaceuticals, Inc.

Inventors: Randolph J. Noelle, Teresa M. Foy

Patent Title: Method for Prolonged Suppression of Humoral Immune Response to a Thymus-Dependent Antigen Therapeutic Agent
Abstract: Methods of suppressing a humoral immune response to a thymus-dependent (TD) antigen are disclosed. The methods involve administering to a subject a TD antigen with an antagonist of a molecule which mediates contact-dependent helper effector functions. In a preferred embodiment, the antagonist is an antagonist of gp39. Primary and secondary humoral immune responses can be suppressed and suppression is prolonged.
Patent Number: 5,942,229
Filed: 06-07-1995
Issued: 08-24-1999
Licensed to: IDEC Pharmaceuticals Corporation

Inventors: Lilian Shen, Michael W. Fanger

Patent Title: Binding Agents Specific for IgA Receptor
Abstract: Binding agents which bind specifically to a receptor for human IgA, including monoclonal antibodies which react specifically to Fc receptor for IgA of human effector cells are disclosed. The binding agents, e.g., antibodies are useful for targeting human effector cells (e.g. macrophages) against a target cell (e.g. a cancer cell, an infectious agent, etc.). For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc-alpha receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can specifically lyse target cells.
Patent Number: 6,018,031
Filed: 11-26-1996
Issued: 01-25-2000
Licensed to: Medarex, Inc.

Inventor: George D. Sorenson

Patent Title: Detection of Soluble Gene Sequences in Biological Fluids
Abstract: Methods are provided for detecting and quantitating gene sequences, such as mutated genes and oncogenes, in biological fluids. The fluid sample (e.g., plasma, serum, urine, etc.) is obtained, deproteinized and the DNA present in the sample is extracted. The DNA is then amplified using an amplification procedure, such as PCR or LCR, to amplify the mutated gene sequence. In one embodiment, the DNA is contacted with a peptide nucleic acid prior to or during the amplification procedure. lyse target cells.
Patent Number: 6,020,124
Filed: 06-07-1995
Issued: 02-01-2000

Inventors: Kendall A. Smith, Carol Beadling

Patent Title: Nucleic Acids Encoding CR1 Fusion Protein, Vector, Transfected Cell and Expression
Abstract: A method for producing a complementary DNA (cDNA) library enriched in ligand-inducible genes of a cell is described. The method includes activating a cellular ligand receptor for a predetermined period of time in the presence of labelled RNA precursors and a substance which enhances the level of RNA in the cell. The RNA precursors are incorporated into the RNA synthesized by the cell in response to receptor activation. The labelled RNA is separated from unlabelled RNA and used to prepare cDNA. The cDNA is cloned into host cells to provide a cDNA library of cDNA-containing clones, which is then screened for clones containing ligand-induced genes. Also described are several novel ligand-induced genes identified using the method of the invention.
Patent Number: 6,020,155
Filed: 06-05-1995
Issued: 02-01-2000

Inventor: Ruth W. Craig

Patent Title: Myeloid Cell Leukemia Associated Gene mcl-1
Abstract: A gene, mcl-1, of the bcl-2 family is disclosed along with its nucleotide and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of utilizing the mcl-1 nucleotide and polypeptide sequences..
Patent Number: 6,020,466
Filed: 12-15-1998
Issued: 02-01-2000
Licensed to: IDUN Pharmaceuticals, Inc.

Inventors: Joseph W. Inselburg, David J. Bzik

Patent Title: Gene Encoding Protein Antigens of Plasmodium Falciparum +B and Uses Therefor
Abstract: A Plasmodium falciparum gene encoding immunogenic SERA protein has been isolated by (a) systematically screening a lambda gt11 recombinant DNA expression library with a murine monoclonal antibody directed against protein antigens of this pathogen, and (b) systematically screening a lambda gt11 genomic cDNA and oligonucleotide probes directed against this pathogen. A 111 kDa protein has been shown to have immunogenic activity against parasite inhibitory antibodies. The gene encoding this protein, including the signal sequence and regulatory sequence in the adjacent 5' flanking sequence has been isolated and sequenced. Isolation and characterization of genes encoding major protein antigens of P. falciparum make it possible to develop reagents useful in the diagnosis, prevention and treatment of malaria. In addition, the signal sequences or regulatory sequences of this gene can be used to stimulate the production of other useful genetic products.
Patent Number: 6,024,966
Filed: 11-07-1994
Issued: 02-15-2000

Inventor: Victor F. Petrenko

Patent Title: Systems and Methods for Modifying Ice Adhesion Strengt
Abstract: The invention includes system for modifying ice adhesion strength of ice adhered to an object. The system includes an electrode that is electrically insulated from the object and a DC source, e.g., a battery, coupled to the object and the electrode. The source generates a DC bias to an interface between the ice and the object when the ice completes the circuit. The object is conductive or is doped as a semiconductor so that the DC bias applies a voltage to the interface which modifies the ice adhesion strength selectively as compared to the ice adhesion strength with substantially zero bias voltage at the interface. The strength can be increased or decreased relative to its static state (i.e., the state without applied voltage). In this manner, ice such as ice on an aircraft wing can be removed with less work. The system preferably includes an electrically insulating material disposed between the object and the electrode; the insulating material is substantially conformal to the object and the electrode. In most applications, the electrode includes a grid electrode shaped to conform to a surface of the object and each point of the grid electrode is in electrical contact with the source. Accordingly, a grid insulator is generally disposed between the object and the grid electrode. The invention has high applicability to objects such as an aircraft wing, an automobile windshield, a bottom of a ski, a heel or sole or a boot or shoe, and an outer material of a power line. The invention also includes a ferroelectric, ferromagnetic or semiconductor coating applied to power lines to auto-regulate the temperature of the lines to just above the melting point.
Patent Number: 6,027,075
Filed: 06-15-1998
Issued: 02-22-2000
Licensed to: BFGoodrich Aerospace, Ice-Tek Ventures, LLC, Advanced Recycling Sciences, Inc., Torvec, Inc., Ice Engineering, LLC

Inventors: Kendall A. Smith, Carol Beadling

Patent Title: Nucleic Acids Encoding CR6 Polypeptide Vector and Transformed Cell Thereof, and Expression Thereof
Abstract: Early-induced genes by interleukin-2 (IL-2) have various DNA sequences. This patent describes a nucleotide segment, such as SEQ. ID No: 11, SEQ. ID No. 31, or encoding a polypeptide of amino acids 1-159 of SEQ. ID No: 12, antibody binding homologues thereof, antibody binding fragments, and fusion proteins thereof, alleles or naturally occurring mutants of the polyribonucleotides, and anti-sense polyribonucleotides thereof. Also provided are proteins, homologues, fragments, fusion proteins, vectors, transfected hosts, animal models, probes, and other related technology.
Patent Number: 6,027,914
Filed: 06-05-1995
Issued: 02-22-2000

Inventors: Bruce E. Kemp, David I. Stapleton, Kenneth I. Mitchelhill, Lee A. Witters

Patent Title: AMP Activated Protein Kinase
Abstract: PCT No. PCT/US97/00270 Sec. 371 Date Oct. 7, 1998 Sec. 102(e) Date Oct. 7, 1998 PCT Filed Jan. 7, 1997 PCT Pub. No. WO97/25341 PCT Pub. Date Jul. 17, 1998 Polynucleotides of AMPK Alpha 1, AMPK Beta and AMPK gamma and polypeptides and biologically active fragments encoded thereby are provided. Vectors and host cells containing these polynucleotides are also provided. In addition, methods of preparing polypeptides and antibodies targeted against these polypepitdes are provided.
Patent Number: 6,124,125
Filed: 10-07-1998
Issued: 09-26-2000
Licensed to: Mercury Therapeutics, Inc.

Inventors: Mary Lou Guerinot, David J. Eide

Patent Title: Metal-Regulated Transporters and Uses Therefor
Abstract: Isolated nucleic acid molecules encoding novel members of the MRT family of polypeptides which include, in a preferred embodiment, at least one transmembrane domain having at least about 30 percent, more preferably at least about 50 percent, 55 percent, 60 percent, 70 percent, 80 percent or 90 percent amino acid sequence identity with SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:14 and/or at least one histidine rich domain, are described. The MRT polypeptides of the invention are capable of transporting metals such as Fe(II), Cd, Co, Mn, Pb, Hg and Zn. Transgenic plants in which expression of an MRT polypeptide of the invention is altered are also described. These transgenic plants can be used to remove pollutants from soil or as nutritional supplements to treat iron- or zinc-deficiency. Antisense nucleic acid molecules, recombinant expression vectors containing nucleic acid molecules of the invention, and host cells into which the expression vectors have been introduced are also described. The invention further provides isolated MRT polypeptides, fusion polypeptides and active fragments thereof. Therapeutic methods utilizing compositions of the invention are also provided.
Patent Number: 6,162,900
Filed: 06-30-1998
Issued: 12-19-2000
Licensed to: Paradigm Genetics, Inc.

Inventors: Alan Eastman, Ronald Krieser

Patent Title: Deoxyribonuclease II Proteins and cDNAS
Abstract: The present invention provides cDNAs encoding deoxyribonuclease II and isolated, purified deoxyribonuclease II proteins. Antibodies against this protein and antisense agents targeted to a cDNA or corresponding mRNA encoding deoxyribonuclease II are provided. In addition, methods of identifying and using modulators of deoxyribonuclease II activity and apoptosis are described.
Patent Number: 6,184,034
Filed: 03-23-1999
Issued: 02-06-2001

Inventors: Gordon W. Gribble, Gary D. Jaycox, Michael Mosher

Patent Title: Bis(9-aminoacridine) DNA Intercalating Agents Having Antitumor Activity
Abstract: A series of bis-acridinyl DNA intercalating agents with anticancer cell activity represented by formula (I), where Z is a linear arrangement of multiple aromatic rings, containing at least three aromatic rings, or at least two alicyclic rings, said rings being linked in a 1,4 or 1,3 manner are provided. Methods of inhibiting cancer cells and treating patients having cancer with these agents are also provided.
Patent Number: 6,187,787
Filed: 02-15-2000
Issued: 02-13-2001

Inventor: Ruth W. Craig

Patent Title: Myeloid Cell Leukemia Associated Gene mcl-1
Abstract: A gene, mcl-1, of the bcl-2 family is disclosed along with its nucleotide and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of utilizing the mcl-1 nucleotide and polypeptide sequences.
Patent Number: 6,200,763
Filed: 08-20-1999
Issued: 03-13-2001
Licensed to: IDUN Pharmaceuticals, Inc.

Inventors: George T. Blike, Nicholas Simon Faithfull, Glenn Rhoades

Patent Title: System and Method for Displaying Medical Process Diagrams
Abstract: A system and method is described for determining and graphically displaying oxygenation states of a patient in real time. The system is non-invasive and can display information to a physician that is intuitive. Various display objects are described for illustrating the output of oxygenation values. The display objects reflect the in vivo physiology that they measure, thus making interpretation of the measured values very intuitive.
Patent Number: 6,234,963
Filed: 02-09-1998
Issued: 05-22-2001

Inventor: John A. Baron

Patent Title: Composition and Method for Reducing the Risk of Carcinogenesis
Abstract: A method for reducing a risk of carcinogenesis in a subject comprising administering a dose of calcium to the subject that is effective to reduce carcinogenesis. Particularly provided is a method for reducing the risk of recurrence of colorectal adenomas, comprising administering a dose of calcium carbonate effective to reduce the risk of colorectal adenomas. In an example, 1,200 mg of elemental calcium (supplied in 3,000 mg of calcium carbonate) administered twice daily resulted in decreased risk of recurrent colorectal adenomas in patients with a history of colorectal adenomas.
Patent Number: 6,251,439
Filed: 12-15-1999
Issued: 06-26-2001
Licensed to: Wyeth Consumer Health Care

Inventors: Randolph J. Noelle, Teresa M. Foy, Alejandro Aruffo, Jeffrey A. Ledbetter

Patent Title: Method of Treating Graft-Versus-Host Disease with Anti-GP39 Antibodies and Bone Marrow Cells
Abstract: A method of treating graft-vs-host diseases by administration of bone marrow and an anti-gp39 antibody specific to human gp39 is provided.
Patent Number: 6,312,692
Filed: 04-30-1998
Issued: 11-06-2001
Licensed to: IDEC Pharmaceuticals Corporation

Inventors: Gordon W. Gribble, Tadashi Honda, Michael B. Sporn, Nanjoo Suh

Patent Title: Therapeutic Compounds and Methods of Use
Abstract: Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.
Patent Number: 6,326,507
Filed: 06-17-1999
Issued: 12-04-2001

Inventors: Randolph J. Noelle, Eric Claassen

Patent Title: Method to Treat Multiple Sclerosis with GP39-specific Antibodies
Abstract: Method for the treatment of multiple sclerosis and other T cell mediated autoimmune disorders is described. The method involves administering to a subject a therapeutically effective amount of an antagonist of a receptor on a surface of a T cell which mediates contact dependent helper effector functions, for example, an anti-gp39 antibody.
Patent Number: 6,328,964
Filed: 05-18-1998
Issued: 12-11-2001
Licensed to: IDEC Pharmaceuticals Corporation

Inventors: Alan R. Eastman, Ronald J. Krieser

Patent Title: Deoxyribonuclease II.beta. Proteins and cDNAs
Abstract: The present invention provides cDNAs encoding deoxyribonuclease II.beta. and isolated, purified deoxyribonuclease II.beta. proteins. Antibodies against this protein and antisense agents targeted to a cDNA or corresponding mRNA encoding deoxyribonuclease II.beta. are provided. In addition, methods of identifying and using modulators of deoxyribonuclease II.beta. activity are described.
Patent Number: 6,358,723
Filed: 05-19-2000
Issued: 03-19-2002

Inventors: Randolph J. Noelle, Fiona H. Durie

Patent Title: Methods for Inducing T Cell Unresponsiveness to Donor Tissue or Organ in A Recipient with gp39 Antagonists
Abstract: Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which expresses donor antigens and which has a ligand on the cell surface which interacts with a receptor on the surface of a recipient T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor which inhibits interaction of the ligand with the receptor. In a preferred embodiment, the allogeneic or xenogeneic cell is a B cell, preferably a resting B cell, and the molecule on the surface of the T cell which mediates contact-dependent helper effector function is gp39. A preferred gp39 antagonist is an anti-gp39 antibody. The allogeneic or xenogeneic cell and the gp39 antagonist are typically administered to a transplant recipient prior to transplantation of the tissue or organ. The methods of the invention can be used to induce T cell tolerance to transplants such as liver, kidney, heart, lung, skin, muscle, neuronal tissue, stomach and intestine. A method for treating diabetes comprising administering to a subject allogeneic or xenogeneic cells expressing donor antigens, a gp39 antagonist and pancreatic islets is also disclosed.
Patent Number:
6,375,950
Filed: 01-05-1999
Issued: 04-23-2002
Licensed to: IDEC Pharmaceuticals Corporation

Inventors: Lloyd H. Kasper, Imtiaz A. Khan

Patent Title: Method of Augmenting T cell-Mediated Immunity Against Toxoplasma Gondii
Abstract: A method of augmenting T cell-mediated immunity against Toxoplasma gondii is provided. Immunization with Toxoplasma gondii soluble parasite antigen and exogenous rIL-15 was found to protect against Toxoplasma gondii infection.
Patent Number: 6,399,077
Filed: 05-19-1999
Issued: 06-04-2002

Inventors: Joyce A. DeLeo, Peter Schubert

Patent Title: Compositions and Method for Decreasing Neuropathic Pain
Abstract: Compositions containing propentofylline, and methods for treating neuropathic pain with such compositions, are disclosed.
Patent Number: 6,413,976
Filed: 02-04-2002
Issued: 07-02-2002

Inventor: Victor F. Petrenko

Patent Title: Systems and Methods for Modifying Ice Adhesion Strength
Abstract: The invention includes system for modifying ice adhesion strength of ice adhered to an object. The system includes an electrode that is electrically insulated from the object and a DC source, e.g., a battery, coupled to the object and the electrode. The source generates a DC bias to an interface between the ice and the object when the ice completes the circuit. The object is conductive or is doped as a semiconductor so that the DC bias applies a voltage to the interface which modifies the ice adhesion strength selectively as compared to the ice adhesion strength with substantially zero bias voltage at the interface. The strength can be increased or decreased relative to its static state (i.e., the state without applied voltage). In this manner, ice such as ice on an aircraft wing can be removed with less work. The system preferably includes an electrically insulating material disposed between the object and the electrode; the insulating material is substantially conformal to the object and the electrode. In most applications, the electrode includes a grid electrode shaped to conform to a surface of the object and each point of the grid electrode is in electrical contact with the source. Accordingly, a grid insulator is generally disposed between the object and the grid electrode. The invention of one embodiment incorporates porous materials to selectively dope the ice on a surface; and the invention of another embodiment incorporates self assembling monolayers to reduce the strength of hydrogen bonding between ice and metals. In one embodiment, the invention provides for coating a power line that changes properties with temperature such that the coating melts snow in freezing conditions.
Patent Number: 6,413,976
Filed: 06-12-2001
Issued: 08-06-2000
Licensed to: BFGoodrich Aerospace, Ice-Tek Ventures, LLC, Advanced Recycling Sciences, Inc., Torvec, Inc., Ice Engineering, LLC

Inventors: Alan R. Eastman, Gordon W. Gribble

Patent Title: Compositions and Methods to Enhance Cancer Chemotherapy in p53 Defective Tumors
Abstract: Compositions which abrogate DNA damage induced cell cycle arrest thereby enhancing the cell killing activity of DNA damaging anticancer agents for use in the treatment of cancer, and in particular, p53 defective cancers are provided.
Patent Number: 6,472,385
Filed: 08-08-2000
Issued: 10-29-2002

Inventors: B. Stuart Trembly, Paul Manganiello, P. Jack Hoopes

Patent Title: System and Methods for Fallopian Tube Occlusion
Abstract: The invention provides systems, methods for 14 treatment, and occlusion of the fallopian tube. An elongated catheter (22) is placed into the isthmic region (14) of the fallopian tube (16) in a trans-cervical trans-uterine fashion, and a mono-pole antenna (92) is disposed within a distal end of the catheter. The antenna radiates microwave energy in resonance to a drive frequency into tissue of the isthmic region without physical contact between the mono-pole antenna, and the tissue. This heating causes occlusion after a period of time. Typically, the catheter, and the mono-pole antenna are disposable after one treatment. In the preferred embodiment, the antenna is formed from an extension of the inner conductor of a coaxial cable coupled to a microwave generator. A power control section (24) can be used to control, and apply the appropriate microwave power to the fallopian tube tissue. In addition, the invention preferably incorporates a microwave immune thermometry probe within the catheter to measure the temperature of the tissue in real time.
Patent Number: 6,485,486
Filed: 08-04-1998
Issued: 11-26-2002

Inventor: John A. Baron

Patent Title: Composition and Method for Reducing the Risk of Carcinogenesis
Abstract: A method for reducing a risk of carcinogenesis in a subject comprising administering a dose of calcium to the subject that is effective to reduce carcinogenesis. Particularly provided is a method for reducing the risk of recurrence of colorectal adenomas, comprising administering a dose of calcium carbonate effective to reduce the risk of colorectal adenomas. In an example, 1,200 mg of elemental calcium (supplied in 3,000 mg of calcium carbonate) administered twice daily resulted in decreased risk of recurrent colorectal adenomas in patients with a history of colorectal adenomas.
Patent Number: 6,488,966
Filed: 03-27-2001
Issued: 12-03-2002
Licensed to: Wyeth Consumer Health Care

Inventors: Paul A. Beisswenger, Benjamin S. Szwergold

Patent Title: Treatment for Complications of Type II Diabetes
Abstract: A method is disclosed of lowering plasma levels of _-dicarbonyl precursors of advanced glycation end-products, such as methylglyoxal, in a patient having Type II diabetes by administering metformin in a dosage from 25 to 50 percent in excess of its antidiabetic therapeutic regimen. The high dosage of metformin acts to reduce plasma levels of _-dicarbonyl compounds by a mechanism distinct from that whereby it exerts its antidiabetic activity.
Patent Number: 6,498,193
Filed: 12-13-2000
Issued: 12-24-2002

Inventors: Ann C. Griffin, William F. Hickey

Patent Title: Detection Methods for Type I Diabetes
Abstract: Proinsulin peptide compounds that modulate an immunological response by T cells of Type I diabetic subjects are disclosed. The proinsulin peptide compounds of the invention are preferable derived from a region of proinsulin that spans the junction between the B chain and C peptide of proinsulin. Pharmaceutical compositions comprising the proinsulin peptide compounds are also disclosed. An immunological response to a proinsulin peptide compound of the invention can be used as an indicator of Type I diabetes in a subject. Accordingly, the invention provides diagnostic assays for Type I diabetes using the proinsulin peptide compounds. Methods for inhibiting the development or progression of Type I diabetes in a subject by administering a proinsulin peptide compound are also disclosed.
Patent Number: 6,509,165
Filed: 06-06-1995
Issued: 01-21-2003

Related releases:

Public benefits from Dartmouth discoveries
Fibromyalgia treatment developed and licensed

Dartmouth has television (satellite uplink) and radio (ISDN) studios available for domestic and international live and taped interviews. For more information, call 603-646-3661 or see our Radio, Television capability webpage.

Recent Headlines from Dartmouth News: